Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gaborit Benjamin¹²^ORCID,Dailly Eric³,Vanhove Bernard⁴,Josien Régis⁵⁶,Lacombe Karine⁷,Dubee Vincent⁸,Ferre Virginie²⁹,Brouard Sophie⁶,Ader Florence¹⁰¹¹,Vibet Marie-Anne¹²,Le Thuaut Aurélie¹²,Danger Richard⁶,Flet Laurent¹³,Omnes Anne¹²,Berly Laetitia¹²,Chiffoleau Anne¹²,Jobert Alexandra¹²,Duvaux Odile⁴,Raffi François¹²

Affiliation:

1. Department of Infectious Disease, Nantes University Hospital, Nantes, France

2. INSERM CIC1413, Nantes University Hospital, Nantes, France

3. Clinical Pharmacology Department, CHU Nantes, Nantes, France

4. Xenothera, Nantes, France

5. Laboratoire d’Immunologie, CIMNA, CHU Nantes, Nantes, France

6. Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, ITUN, CHU Nantes, Nantes, France

7. Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, AP-HP, Hôpital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, Paris, France

8. Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire d’Angers, Angers, France

9. Virology Laboratory University Hospital, Nantes, France

10. Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France

11. Département des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France

12. CHU Nantes, Sponsor Department, Nantes, France

13. CHU Nantes, Pharmacy Department, Nantes, France

Abstract

We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related moderate pneumonia. The objective was to evaluate the optimal dose and safety of XAV-19 during this first administration to patients with COVID-19-related moderate pneumonia.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01237-21

Reference21 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. John Hopkins Coronavirus Resource Center. 2021. COVID-19 map. Johns Hopkins Coronavirus Resource Center, Baltimore, MD.

3. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

4. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit

5. Dexamethasone in Hospitalized Patients with Covid-19

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the structural and functional dimensions of SARS-CoV2 proteins in the context of COVID-19 pathogenesis and therapeutics;International Journal of Biological Macromolecules;2024-10

2. Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review);Molecular Medicine Reports;2024-06-26

3. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19;Frontiers in Immunology;2024-04-17

4. First-in-human Study With LIS1, a Next-generation Porcine Low Immunogenicity Antilymphocyte Immunoglobulin in Kidney Transplantation;Transplantation;2024-02-29

5. New polyclonal antibodies, inhibit selectively tumor growth and invasion and synergize with immune checkpoint inhibitors;JCI Insight;2023-12-12